Statistics
Total Visits
Views | |
---|---|
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells(legacy) | 151 |
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells(legacy) | 91 |
Total Visits per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells | 1 | 7 | 1 | 4 | 2 | 6 | 3 |
File Downloads
Views |
---|
Top Country Views
Views | |
---|---|
United States | 87 |
China | 16 |
Vietnam | 12 |
France | 11 |
Netherlands | 8 |
Australia | 6 |
Canada | 1 |
Ireland | 1 |
Iran | 1 |
Singapore | 1 |
Top City Views
Views | |
---|---|
Ashburn | 23 |
Hanoi | 12 |
Buffalo | 10 |
Rotterdam | 8 |
Cambridge | 6 |
Fairfield | 6 |
Kaleen | 6 |
Zhengzhou | 6 |
New York | 4 |
Seattle | 3 |